Intacs Prescription Inserts for Keratoconus Patients

Recruiting N/A Interventional Study
Keratoconus
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
25 (estimated)
Sponsor
University of Texas Southwestern Medical Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The US food and Drug Administration (FDA) originally approved INTACS prescription inserts in April 1999 for the correction of low levels of nearsightedness (-1.00 to -3.00 diopters). Additional clinical data have shown that INTACS are safe for the treatment of keratoconus, in July 2004, FDA approved INTACS inserts for the treatment of keratoconus as a Humanitarian Use Device (FDA approval letter a…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Who have experienced a progressive deterioration in their vision, such thot they can no longer achieve adequate functional vision on a daily basis with their contact lenses or spectacles; Who are 21 years of age or older; Who have clear central corneas; Who have a corneal thickn…
Contacts

Peter Chen, PhD

214-648-3837

Peter.Chen@UTSouthwestern.edu

CONTACT

Asha Varghese, MS

214-648-3087

Asha.Varghese@UTSouthwestern.edu

CONTACT